Insulin degludec and insulin aspart: Novel insulins for the management of diabetes mellitus

Therapeutic Advances in Chronic Disease

Volumn 6, Issue 6, 2015, Pages 375-388

  Atkin, Stephen ^a   Javed, Zeeshan ^b   Fulcher, Gregory ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^b HULL ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Basal bolus regimen; Hypoglycaemia; Insulin aspart; Insulin degludec; Insulin degludec insulin aspart; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; INSULIN ASPART; INSULIN ASPART PLUS INSULIN DEGLUDEC; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; PHENOL DERIVATIVE; ZINC;

DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PH; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84945190388     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622315608646     Document Type: Review

References (54)

1. Abrahamson M. (2010) Basal insulins: pharmacological properties and patient perspectives. Prim Care Diabetes 4(Suppl. 1): S19–S23.
2. Bretzel R. Arnolds S. Medding J. Linn T. (2004) A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70 / 30) in patients with type 2 diabetes. Diabetes Care 27: 1023–1027.
3. Brod M. Alolga S. Meneghini L. (2014) Barriers to initiating insulin in type 2 diabetes patients: development of a new patient education tool to address myths, misconceptions and clinical realities. Patient 7: 437–450.
4. Brod M. Pohlman B. Wolden M. Christensen T. (2013) Non-severe nocturnal hypoglycemic events: experience and impacts on patient functioning and well-being. Qual Life Res 22: 997–1004.
5. Brod M. Rana A. Barnett A. (2012) Impact of self-treated hypoglycaemia in type 2 diabetes: a multinational survey in patients and physicians. Curr Med Res Opin 28: 1947–1958.
6. Budnitz D. Lovegrove M. Shehab N. Richards C. (2011) Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 365: 2002–2012.
7. Cengiz E. Swan K. Tamborlane W. Sherr J. Martin M. Weinzimer S. (2012) The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin. Diabetes Care 35: 690–692.
8. Cooper J. Pieber T. Cariou B. Endahl L. Zacho J. Rodbard H. (2014) Treatment intensification with IDegAsp BID vs IDeg OD plus IAsp in insulin-treated patients with type 2 diabetes: a randomised, controlled phase 3 trial. Diabetologia 57: S69.
9. Dailey G. Rosenstock J. Moses R. Ways K. (2004) Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 27: 2363–2368.
10. FDA. (2012) Briefing Document. NDA 203313 and NDA 203314 Insulin Degludec and Insulin Degludec/Aspart. Silver Spring, MD: Food and Drug Administration. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM327015.pdf; accessed July 2015.
11. Franek E. Haluzík M. Canecki Varžić S. Sargin M. Macura S. Zacho J. et al. (2014) IDegAsp provides superior FPG control and reduced hypoglycaemia vs BIAsp 30 in insulin-naive adults with type 2 diabetes: a randomised phase 3 trial. Diabetologia 57: S380.
12. Fulcher G. Christiansen J. Bantwal G. Polaszewska-Muszynska M. Mersebach H. Andersen T. et al. (2014) Comparison of insulin degludec / insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care 37: 2084–2090.
13. Garber A. (2009) Insulin intensification strategies in type 2 diabetes: when one injection is no longer sufficient. Diabetes Obes Metab 11: 14–18.
14. Garber A. King A. Del P. Sreenan S. Balci M. Munoz-Torres M. et al. (2012) Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 379: 1498–1507.
15. Haak T. Tiengo A. Draeger E. Suntum M. Waldhäusl W. (2005) Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 7: 56–64.
16. Havelund S. (2013) Insulin Degludec (IDeg) and Insulin Aspart (IAsp) can be Coformulated such that the Formation of IDeg Multi-hexamers and IAsp Monomers is Retained Upon Subcutaneous Injection. Poster presented at the American Diabetes Association, 21–25 June 2013, Chicago, USA.
17. Heinemann L. Heise T. Jorgensen L. Starke A. (1993) Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabet Med 10: 535–539.
18. Heise T. Nosek L. Bøttcher S. Hastrup H. Haahr H. (2012 a) Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 14: 944–950.
19. Heise T. Hermanski L. Nosek L. Feldman A. Rasmussen S. Haahr H. (2012 b) Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 14: 859–864.
20. Heise T. Nosek L. Roepstorff C. Chenji S. Klein O. Haahr H. (2014) Distinct prandial and basal glucose-lowering effects of insulin degludec / insulin aspart (IDegAsp) at steady state in subjects with type 1 diabetes mellitus. Diabetes Ther 5: 255–265.
21. Heise T. Tack C. Cuddihy R. Davidson J. Gouet D. Liebl A. et al. (2011) A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care 34: 669–674.
22. Heller S. (2004) Weight gain during insulin therapy in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 65(Suppl. 1): S23–S27.
23. Heller S. Buse J. Fisher M. Garg S. Marre M. Merker L. et al. (2012) Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 379: 1489–1497.
24. Hirsch I. Bode B. Courreges J. Dykiel P. Franek E. Hermansen K. et al. (2012) Insulin degludec / insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care 35: 2174–2181.
25. Hollander P. Cooper J. Bregnhøj J. Pedersen C. (2008) A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 30: 1976–1987.
26. Home P. (2012) The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab 14: 780–788.
27. Ilag L. Kerr L. Malone J. Tan M. (2007) Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther 29: 1254–1270.
28. Inzucchi S. Bergenstal R. Buse J. Diamant M. Ferrannini E. Nauck M. et al. (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35: 1364–1379.
29. Jonassen I. Havelund S. Hoeg-Jensen T. Steensgaard D. Wahlund P. Ribel U. (2012) Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 29: 2104–2114.
30. Kaneko S. Chow F. Choi D. Taneda S. Hirao K. Park Y. et al. (2015) Insulin degludec / insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial. Diabetes Res Clin Pract 107: 139–147.
31. Kurtzhals P. Heise T. Strauss H. Bøttcher S. Granhall C. Haahr H. et al. (2011) Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia 54: S426.
32. Leiter L. Yale J. Chiasson J. Harris S. Kleinstiver P. Sauriol L. (2005) Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes 29: 186–192.
33. Liebl A. Prusty V. Valensi P. Kawamori R. Christiansen J. Palmer A. et al. (2012) Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings. Drugs 72: 1495–1520.
34. Lundkvist J. Berne C. Bolinder B. Jönsson L. (2005) The economic and quality of life impact of hypoglycemia. Eur J Health Econ 6: 197–202.
35. Meneghini L. Atkin S. Gough S. Raz I. Blonde L. Shestakova M. et al. (2013) The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care 36: 858–864.
36. Monnier L. Lapinski H. Colette C. (2003) Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 26: 881–885.
37. Niskanen L. Leiter L. Franek E. Weng J. Damci T. Muñoz-Torres M. et al. (2012) Comparison of a soluble co-formulation of insulin degludec / insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol 167: 287–294.
38. Nosek L. Heise T. Klein O. Coester H. Roepstorff C. Svendsen A. et al. (2013) Insulin Degludec / insulin Aspart Produces a Dose-proportional Glucose-lowering Effect in Subjects with Type 1 Diabetes Mellitus. Poster presented at the European Association for the Study of Diabetes, 23–27 September 2013, Barcelona, Spain.
39. Novo Nordisk (2009) Levemir (Insulin Detemir) Summary of Product Characteristics EPAR. Available at: http://www.ema.europa.eu/ema/ (accessed September 2015).
40. Novo Nordisk (2013) Ryzodeg (70% Insulin Degludec/30% Insulin Aspart) Summary of Product Characteristics EPAR. Available at http://www.ema.europa.eu/ema/ (accessed September 2015).
41. Onishi Y. Ono Y. Rabøl R. Endahl L. Nakamura S. (2013) Superior glycaemic control with once-daily insulin degludec / insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes Metab 15: 826–832.
42. Peyrot M. Barnett A. Meneghini L. Schumm-Draeger P. (2012) Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 29: 682–689.
43. Raskin P. Gylvin T. Weng W. Chaykin L. (2009) Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 25: 542–548.
44. Ratner R. Gough S. Mathieu C. Del Prato S. Bode B. Mersebach H. et al. (2013) Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 15: 175–184.
45. Ross S. Zinman B. Campos R. Strack T. ; Canadian Lispro Study Group. (2001) A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med 24: 292–298.
46. Russell-Jones D. Simpson R. Hylleberg B. Draeger E. Bolinder J. (2004) Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 26: 724–736.
47. Sanofi-Aventis (2010) Lantus (Insulin Glargine) Summary of Product Characteristics EPAR. Available at: http://www.ema.europa.eu/ema/ (accessed September 2015).
48. Tibaldi J. (2014) Evolution of insulin: from human to analog. Am J Med 127: S25–S38.
49. Vaag A. Christiansen J. Niskanen L. Johansen T. Rasmussen S. Fulcher G. (2014) IDegAsp lowers the rate of hypoglycaemia vs biphasic insulin aspart 30 in adults with type 2 diabetes achieving glycaemic target (HbA1c <70%): a meta-analysis. Diabetologia 57: S400.
50. Vaag A. Christiansen J. Niskanen L. Rasmussen S. Johansen T. Fulcher G. (2013) Lower rates of overall, nocturnal and severe hypoglycaemia during maintenance treatment with IDegAsp vs biphasic insulin aspart 30 in patients with type 2 diabetes mellitus: a meta-analysis. Diabetologia 56: S83.
51. Vaag A. Lund S. Lund S. (2012) Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. Eur J Endocrinol 166: 159–170.
52. Vora J. Christensen T. Rana A. Bain S. (2014) Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther 5: 435–446.
53. Vora J. Hollander P. Tamer S. Johansen T. Bergenstal R. (2012) Insulin Degludec Does Not Increase Antibody Formation Compared to Insulin Glargine: An Evaluation of Phase 3a Clinical Trials. Poster presented at the European Association for the Study of Diabetes, 1–5 October 2012, Berlin, Germany.
54. Zinman B. Philis-Tsimikas A. Cariou B. Handelsman Y. Rodbard H. Johansen T. et al. (2012) Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 35: 2464–2471.